Skip to main content
Currently Reading
GenXys HealthCare Systems announces completion of oversubscribed seed round financing to enable continued market penetration with acclaimed precision prescribing software
PRWeb
FacebookTwitterEmail
VANCOUVER, British Columbia (PRWEB) March 01, 2021
GenXys, a health tech company focused on pharmacogenetic enhanced prescribing automation software, is pleased to announce that it has closed an oversubscribed seed round at $3 million. Led by Green Shield Canada (GSC), with key investors including TELUS Ventures, Esplanade Ventures, Nimbus Synergies, and the Business Development Bank of Canada (BDC Capital).
GenXys provides evidence-based medication decision support tools with embedded pharmacogenetics to enable precision prescribing seamlessly at the point of care. Building on recent successes in the Canadian and US markets, the company plans to accelerate their expansion in the North American market meeting the needs of genetic lab companies,